1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
DelMar Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
+0.00
- -
232,279.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-8
-4
-9
-8
-11
-8
-9
-38
-23
-15
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
4
2
6
7
5
2
- -
9
9
- -
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
-1
5
7
5
2
- -
11
12
1
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
11
10
10
Shares Outstanding
2
10
39
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'24
Total Current Assets
1
1
7
Cash, Cash Equivalents & STI
- -
1
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
2
1
Payables & Accruals
3
2
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,290.49%
738.09%
-93.8%
Free Cash Flow
4,856.63%
18.97%
-40.68%
Net Income, GAAP
4,411.54%
45.82%
-35.36%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
7,036.09%
-85.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert E. Hoffman CPA
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
United States of America
Similar Companies
Race Oncology Limited (RAONF)
Biohaven Ltd. (BHVN)
Phio Pharmaceuticals Corp. (PHIOW)
Alexion Pharmaceuticals, Inc. (ALXN)
BioInvent International AB (publ) (BINV.ST)
F-star Therapeutics, Inc. (FSTX)
Business
DelMar Pharmaceuticals, Inc. (OTC: DMPWW) is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies for patients failing or resistant to current treatments; its lead product candidate, VAL-083, is a first-in-class small-molecule DNA-targeting chemotherapeutic agent that induces DNA double-strand breaks and cancer cell death, with clinical activity demonstrated against glioblastoma multiforme (GBM), ovarian cancer, pediatric central nervous system tumors, and other solid tumors including non-small cell lung cancer and head and neck cancers; VAL-083 has completed preclinical, Phase 1, and Phase 2 trials, including for bevacizumab-refractory and MGMT-unmethylated GBM, and is advancing in biomarker-driven Phase 2 trials such as single-agent recurrent TMZ-resistant GBM at MD Anderson Cancer Center and combination with radiation therapy for newly diagnosed MGMT-unmethylated GBM at Sun Yat-sen University. Founded in 2010 and headquartered in Vancouver, British Columbia, Canada, with research and clinical operations in Menlo Park, California, the company collaborates with global academic and clinical institutions including the National Cancer Institute, Global Coalition for Adaptive Research on the GBM AGILE platform trial, and strategic partners in China for commercial rights to VAL-083 in chronic myelogenous leukemia and lung cancer. In 2020, DelMar merged with Adgero Biopharmaceuticals Holdings, Inc., rebranded as Kintara Therapeutics, Inc. (Nasdaq: KTRA), and raised approximately $19.6 million in a private placement to fund VAL-083 and REM-001 photodynamic therapy development for cutaneous metastatic breast cancer; in 2023, Kintara secured a $2 million NIH grant to reinitiate the REM-001 Phase 3-ready program, treating four patients at Memorial Sloan Kettering by late 2024, while pursuing a merger with TuHURA Biosciences, Inc.